title: Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.
abstract: Recombinant vectors based on adeno-associated virus type 2 (AAV) target the liver efficiently, but the transgene expression is limited to approximately 5% of murine hepatocytes. Viral second-strand DNA synthesis continues to be a rate-limiting step for efficient transduction by the single-stranded AAV (ssAAV) vectors. This is due, in part, to the presence of a cellular chaperone (FK506-binding) protein, FKBP52, phosphorylated forms of which interact with the D-sequence in the inverted terminal repeats of AAV2 genome and inhibit the viral second-strand DNA synthesis. Our previous studies have documented that dephosphorylation of FKBP52 at tyrosine residues by the cellular T-cell protein tyrosine phosphatase (TC-PTP), and at serine/threonine residues by protein phosphatase 5 (PP5) enhances viral second-strand DNA synthesis and consequently, the transgene expression. We have also reported that coinfection with a self-complementary AAV (scAAV)-TC-PTP vector results in up to sixfold increase in the transduction efficiency of conventional ssAAV2 vectors in primary murine hepatocytes in vivo. We reasoned that coinfection with scAAV-TC-PTP and scAAV-PP5 vectors may lead to a further increase in the transduction efficiency of ssAAV2 vectors. We demonstrate here that this strategy does indeed lead to approximately 16-fold increase in the transduction efficiency of conventional ssAAV vectors in primary murine hepatocytes in vivo following tail-vein injections. Neither scAAV2-TC-PTP nor scAAV2-PP5 vectors alone or together had any adverse effect on the hepatocytes. Thus, this coinfection strategy may be useful for achieving expression from recombinant ssAAV2 vectors containing larger genes, such as coagulation factor VIII, which exceed the packaging capacity of scAAV vectors, for the potential gene therapy of hemophilia A.
authors.affiliation: Department of Pediatrics, Division of Cellular and Molecular Therapy, University of Florida College of Medicine, Gainesville, FL 32610-3633, USA.
authors.forename: G R
authors.initials: GR
authors.lastname: Jayandharan
authors.forename: L
authors.initials: L
authors.lastname: Zhong
authors.forename: B
authors.initials: B
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Kachniarz
authors.forename: A
authors.initials: A
authors.lastname: Srivastava
mesh_terms: D000818:Animals; D002460:Cell Line; D004277:DNA, Single-Stranded / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D000229:Dependovirus / Q000235:genetics*; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D006467:Hemophilia A / Q000628:therapy; D022781:Hepatocytes / Q000821:virology; D006801:Humans; D008099:Liver / Q000821:virology*; D051379:Mice; D009687:Nuclear Proteins / Q000235:genetics; D010749:Phosphoprotein Phosphatases / Q000235:genetics; D054578:Protein Tyrosine Phosphatase, Non-Receptor Type 2 / Q000235:genetics; D014161:Transduction, Genetic / Q000379:methods*; D019076:Transgenes
chemical_list: D004277:DNA, Single-Stranded; D004279:DNA, Viral; D009687:Nuclear Proteins; D010749:Phosphoprotein Phosphatases; C089641:protein phosphatase 5; D054578:Protein Tyrosine Phosphatase, Non-Receptor Type 2